Shield’s FDA-approved blood test drives cancer screening growth, pricing power, and cash-flow upside. Click for this GH ...
Guardant Health, Inc. (NASDAQ:GH) is one of the Best Russell 2000 Stocks to Buy Right Now. Wall Street has a positive ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company’s Shield™ ...
Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...
GlobalData on MSN
Guardant and MSD collaborate on companion diagnostics development
Guardant and MSD will evaluate opportunities to develop new oncology therapies using liquid biopsy tests.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
Guardant Health Inc. convinced the Federal Circuit to toss a US patent tribunal’s decision that upheld a University of Washington DNA-sequencing patent underpinning an $83.4 million infringement ...
Guardant Health is signing up to a multiyear deal with Merck & Co. for the U.S. Big Pharma to tap its Infinity Smart platform ...
New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity Reveal is ...
Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results